Epileptic Disorders
MENUA case of repetitive seizures following immune checkpoint inhibitor therapy as a feature of autoimmune encephalitis Volume 23, issue 5, October 2021
- [1] Darvin P., Toor S.M., Sasidharan Nair V., Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50:165.
12 - [2] Kyi C., Postow M.A. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 2014;588:368-376.
2 - [3] O’Byrne K. Stimulating immune responses to fight cancer: basic biology and mechanisms. Asia Pac J Clin Oncol. 2015;11:9-15.
Suppl 1 - [4] Dubey D., David W.S., Reynolds K.L., Chute D.F., Clement N.F., Cohen J.V. Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol. 2020;87:659-669.
5 - [5] Sechi E., Markovic S.N., McKeon A., Dubey D., Liewluck T., Lennon V.A. Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes. Neurology. 2020;95:e2442-e2452.
17 - [6] Vogrig A., Muñiz-Castrillo S., Joubert B., Picard G., Rogemond V., Marchal C. Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry. 2020;91:772-778.
7 - [7] Quek A.M., Britton J.W., McKeon A., So E., Lennon V.A., Shin C. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol. 2012;69:582-593.
5 - [8] Toledano M., Britton J.W., McKeon A., Shin C., Lennon V.A., Quek A.M. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology. 2014;82:1578-1586.
18 - [9] Salam S., Lavin T., Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep. 2016;23:2016.
- [10] Khoja L., Maurice C., Chappell M., MacMillan L., Al-Habeeb A.S., Al-Faraidy N. Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res. 2016;4:175-178.
3 - [11] Feng S., Coward J., McCaffrey E., Coucher J., Kalokerinos P., O’Byrne K. Pembrolizumab-induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors. J Thorac Oncol. 2017;12:1626-1635.
11 - [12] Shah N., Jacob J., Househ Z., Shiner E., Baird L., Soudy H. Unchecked immunity: a unique case of sequential immune-related adverse events with pembrolizumab. J Immunother Cancer. 2019;7:247.
1 - [13] Michot J.M., Bigenwald C., Champiat S., Collins M., Carbonnel F., Postel-Vinay S. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-148.
- [14] Longoria T.C., Tewari K.S. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016;12:1247-1253.
10 - [15] Di Gennaro G., Quarato P.P., Onorati P., Colazza G.B., Mari F., Grammaldo J.G. Localizing significance of temporal intermittent rhythmic delta activity (TIRDA) in drug-resistant focal epilepsy. Clin Neurophysiol. 2003;114:70-78.
1 - [16] Dubey D., Singh J., Britton J.W., Pittock S.J., Flanagan E.P., Lennon V.A. Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia. 2017;58:1181-1189.
7 - [17] Diamond B., Huerta P.T., Mina-Osorio P., Kowal C., Volpe B.T. Losing your nerves? Maybe it's the antibodies. Nat Rev Immunol. 2009;9:449-456.
6 - [18] Brahmer J.R., Lacchetti C., Schneider B.J., Atkins M.B., Brassil K.J., Caterino J.M. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36:1714-1768.
17